Table 1.
Baseline characteristics of the study population.
| PLHIV study population | |
|---|---|
|
| |
| Total, n | 117 |
|
| |
| Demographic and anthropometric measures | |
|
| |
| Gender female, n (%) | 60 (51.3) |
| Age, years | 45.6 (38.0–51.4) |
| Body mass index, kg/m² | 26.3 (24.1–30.0) |
| - Male | 25.4 (23.2–28.2) |
| - Female | 28.0 (24.7–31.6) |
| Type 2 diabetes, n (%) | 5 (4.3) |
| Smoking, n (%) | 5 (4.3) |
| Alcohol consumption, n (%) | 25 (21.4) |
| Creatinine (mg/dL) | 0.80 (0.68–0.92) |
| eGFR (mL/min/1.73m2) | 102.0 (85.0–112.5) |
| HIV-status | |
|
| |
| ART regime (%) | 100 |
| Duration on ART, months | 26 (19.3–33.5) |
| Viral suppression, <40 copies/ml, n (%) | 113 (96.6) |
| CD4 count (cells/mm3) | 392 (241–528) |
| Hypertension status | |
|
| |
| History of hypertension, n (%) | 61 (52.1) |
| Previous antihypertensive treatment, n (%) | 37 (60.7) |
| Monotherapy with D or A or C | 17/1/1 |
| Comb. A + C | 2 |
| Comb. D + A/B/C | 4/2/0 |
| Comb. D + A + C | 6 |
| Comb. D + B + C | 2 |
| Comb. D + A + B + C | 2 |
n, number; eGFR, estimated glomerular filtration rate; D, thiazide diuretic; A, angiotensin converting enzyme inhibitor; B, beta-blocker; C, calcium channel blocker; comb., combination therapy.